Payment overview · 2025
General Payments
$188.13
10 reported records · 7 companies
Healthcare provider profile · identity verified
Abdulkader Dahhan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HARLAN, KY · NPI 1639134794
Verified facts
What the public records show
CMS Open Payments records show Abdulkader Dahhan, M.D. received $188.13 in general payments during 2025 across 10 reported records.
GlaxoSmithKline, LLC. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.99 | 28.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.71 | 17.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.90 | 15.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.54 | 11.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.14 | 10.7% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $15.89 | 8.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.96 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $188.13 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $52.99 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.71 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
325 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Tartrate | Metoprolol Tartrate | 662 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 119 |
| Lisinopril | Lisinopril | 541 | 113 |
| Metformin Hcl | Metformin Hcl | 538 | 114 |
| Gabapentin | Gabapentin | 483 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 465 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 412 | 83 |
| Furosemide | Furosemide | 410 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 410 | 87 |
| Glipizide | Glipizide | 372 | 64 |
| Eliquis | Apixaban | 325 | 39 |
| Meloxicam | Meloxicam | 280 | 64 |
| Omeprazole | Omeprazole | 264 | 51 |
| Simvastatin | Simvastatin | 263 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 247 | 83 |
| Prednisone | Prednisone | 243 | 68 |
| Amoxicillin | Amoxicillin | 232 | 163 |
| Cephalexin | Cephalexin | 229 | 153 |
| Clopidogrel | Clopidogrel Bisulfate | 220 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 50 |
| Losartan Potassium | Losartan Potassium | 203 | 46 |
| Azithromycin | Azithromycin | 198 | 139 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 184 | 31 |
| Allopurinol | Allopurinol | 176 | 38 |
| Lorazepam | Lorazepam | 165 | 30 |
| Ozempic | Semaglutide | 156 | 32 |
| Atenolol | Atenolol | 153 | 31 |
| Ibuprofen | Ibuprofen | 147 | 40 |
| Sertraline Hcl | Sertraline Hcl | 147 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 143 | 65 |
| Potassium Chloride | Potassium Chloride | 140 | 27 |
| Trazodone Hcl | Trazodone Hcl | 139 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 133 | 35 |
| Tramadol Hcl | Tramadol Hcl | 126 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 121 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 18 |
| Januvia | Sitagliptin Phosphate | 116 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 15 |
| Montelukast Sodium | Montelukast Sodium | 115 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 106 | 86 |
| Glimepiride | Glimepiride | 104 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 104 | 21 |
| Clindamycin Hcl | Clindamycin Hcl | 100 | 74 |
| Levofloxacin | Levofloxacin | 100 | 70 |
| Donepezil Hcl | Donepezil Hcl | 98 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 97 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 88 | 30 |
| Diltiazem Hcl | Diltiazem Hcl | 84 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 13 |
| Meclizine Hcl | Meclizine Hcl | 82 | 24 |
| Clonidine Hcl | Clonidine Hcl | 81 | 23 |
| Celecoxib | Celecoxib | 80 | 27 |
| Olanzapine | Olanzapine | 80 | 11 |
| Carvedilol | Carvedilol | 79 | 15 |
| Clonazepam | Clonazepam | 78 | 14 |
| Jardiance | Empagliflozin | 78 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 14 |
| Bumetanide | Bumetanide | 75 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 75 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 42 |
| Buspirone Hcl | Buspirone Hcl | 69 | 13 |
| Fluconazole | Fluconazole | 69 | 35 |
| Diazepam | Diazepam | 66 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 20 |
| Alprazolam | Alprazolam | 63 | suppressed |
| Entresto | Sacubitril/Valsartan | 62 | suppressed |
| Nystatin | Nystatin | 61 | 23 |
| Methocarbamol | Methocarbamol | 60 | 41 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 58 | 50 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 11 |
| Phenobarbital | Phenobarbital | 56 | suppressed |
| Sucralfate | Sucralfate | 54 | 12 |
| Mirtazapine | Mirtazapine | 53 | 14 |
| Spironolactone | Spironolactone | 53 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 15 |
| Tradjenta | Linagliptin | 51 | suppressed |
| Naproxen | Naproxen | 50 | 11 |
| Dexamethasone | Dexamethasone | 48 | 24 |
| Famotidine | Famotidine | 48 | 11 |
| Linzess | Linaclotide | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 46 | 13 |
| Promethazine Hcl | Promethazine Hcl | 46 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | suppressed |
| Nifedipine Er | Nifedipine | 45 | suppressed |
| Novolin R | Insulin Regular, Human | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 45 | 17 |
| Warfarin Sodium | Warfarin Sodium | 45 | 12 |
| Colchicine | Colchicine | 44 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 12 |
| Cilostazol | Cilostazol | 40 | suppressed |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | 12 |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 38 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | suppressed |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | 11 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Humulin R | Insulin Regular, Human | 29 | 11 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 16 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | 14 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Otezla | Apremilast | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Constulose | Lactulose | 19 | 11 |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | 14 |
| Lactulose | Lactulose | 15 | 12 |
| Digoxin | Digoxin | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $188.13 · 10 records | GlaxoSmithKline, LLC. | CAPLYTA, Cologuard Collection Kit, DUPIXENT, GVOKE HYPOPEN, JOURNAVX, NUCALA, NURTEC ODT, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error